Literature DB >> 263346

The evolving clinical course of patients with insulin receptor autoantibodies: spontaneous remission or receptor proliferation with hypoglycemia.

J S Flier, R S Bar, M Muggeo, C R Kahn, J Roth, P Gorden.   

Abstract

Three patients with insulin resistance caused by autoantibodies to the insulin receptor were investigated serially over a 3-yr period. Major changes in carbohydrate metabolism, insulin receptor status, and titer of antireceptor antibodies were observed in each case. In one patient, normalization of glucose tolerance, insulin sensitivity, and receptor binding were associated with a spontaneous fall in the titer of antireceptor antibody. A second, more severely affected patient had two entirely distinct phase to her illness. The first, or hyperglycemic phase, was characterized by insulin resistance, negligible insulin binding to receptors on circulating monocytes, and high titers of circulating antireceptor antibodies. The second phase was characterized by refractory hypoglycemia, in association with proliferation of membrance insulin receptors; these occurred despite persistence of high titers of antireceptor antibody. An unusual heptic lesion, diffuse adenomatosis, was observed during this phase. A third patient showed features of both of the other patients, with spontaneous fall in antibody titer as well as a later phase of receptor proliferation. These studies demonstrate that patients with antibodies to insulin receptors may have a fluctuating clinical course. There may be spontaneous changes in antibody titers as well as independent changes in receptor concentration. Hypoglycemia and hepatic proliferation are newly recognized clinical sequelae in patients with this syndrome.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 263346     DOI: 10.1210/jcem-47-5-985

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  15 in total

Review 1.  Antibodies directed to the insulin receptor. Clinical aspects and applications to the study of insulin action.

Authors:  R De Pirro; P Borboni; M A Marini; A Montemurro; G Sesti; R Lauro
Journal:  J Endocrinol Invest       Date:  1990-12       Impact factor: 4.256

2.  Insulin receptor antibodies causing steroid responsive diabetes mellitus in a patient with myositis.

Authors:  V Fonseca; M A Khokher; P Dandona
Journal:  Br Med J (Clin Res Ed)       Date:  1984-05-26

Review 3.  Chylomicronemia from GPIHBP1 autoantibodies.

Authors:  Kazuya Miyashita; Jens Lutz; Lisa C Hudgins; Dana Toib; Ambika P Ashraf; Wenxin Song; Masami Murakami; Katsuyuki Nakajima; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Lipid Res       Date:  2020-09-18       Impact factor: 5.922

4.  Characterization of insulin receptors in patients with the syndromes of insulin resistance and acanthosis nigricans.

Authors:  R S Bar; M Muggeo; C R Kahn; P Gorden; J Roth
Journal:  Diabetologia       Date:  1980-03       Impact factor: 10.122

5.  Human immunoglobulin G stimulates human adipocyte lipogenesis.

Authors:  M A Khokher; S Janah; P Dandona
Journal:  Diabetologia       Date:  1983-09       Impact factor: 10.122

6.  Insulin resistance and secretion in polycystic ovarian disease.

Authors:  B Bruno; G Poccia; A Fabbrini
Journal:  J Endocrinol Invest       Date:  1985-10       Impact factor: 4.256

Review 7.  Hypoglycemias.

Authors:  F J Service
Journal:  West J Med       Date:  1991-04

8.  Clinical disorders associated with autoantibodies to the insulin receptor. Simulation by passive transfer of immunoglobulins to rats.

Authors:  R F Dons; R Havlik; S I Taylor; K L Baird; S S Chernick; P Gorden
Journal:  J Clin Invest       Date:  1983-09       Impact factor: 14.808

Review 9.  Insulin autoimmune syndrome: from diagnosis to clinical management.

Authors:  Simona Censi; Caterina Mian; Corrado Betterle
Journal:  Ann Transl Med       Date:  2018-09

10.  Intermittent chylomicronemia caused by intermittent GPIHBP1 autoantibodies.

Authors:  Ambika P Ashraf; Kazuya Miyashita; Katsuyuki Nakajima; Masami Murakami; Robert A Hegele; Michael Ploug; Loren G Fong; Stephen G Young; Anne P Beigneux
Journal:  J Clin Lipidol       Date:  2020-01-31       Impact factor: 4.766

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.